US 12,239,686 B2
Immune checkpoint inhibitor combinations
Liv Marie Eike, Tromsø (NO); Ketil André Camilio, Tromsø (NO); Baldur Sveinbjörnsson, Tromsø (NO); Laurence Zitvogel, Villejuif (FR); Takahiro Yamazaki, Villejuif (FR); Oystein Rekdal, Billingstad (NO); and John Sigurd Mjoen Svendsen, Kvaløysletta (NO)
Assigned to LYTIX BIOPHARMA AS, Tromsø (NO)
Filed by LYTIX BIOPHARMA AS, Tromsø (NO)
Filed on Mar. 7, 2024, as Appl. No. 18/598,719.
Application 18/598,719 is a continuation of application No. 17/366,463, filed on Jul. 2, 2021, abandoned.
Application 17/366,463 is a continuation of application No. 15/534,800, granted, now 11,083,774, issued on Aug. 10, 2021, previously published as PCT/EP2015/075722, filed on Nov. 4, 2015.
Claims priority of application No. 1422084 (GB), filed on Dec. 11, 2014; application No. 1506127 (GB), filed on Apr. 10, 2015; and application No. 2015-118495 (JP), filed on Jun. 11, 2015.
Prior Publication US 2024/0293506 A1, Sep. 5, 2024
Int. Cl. A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 38/1729 (2013.01) [A61K 38/08 (2013.01); A61K 39/39533 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 7/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 38/00 (2013.01); A61K 2039/585 (2013.01); A61K 2300/00 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating a tumour in a subject in need thereof, comprising combined, sequential or separate administration to said subject of an immune checkpoint inhibitor and a compound having the following characteristics:
a) consisting of 9 amino acids in a linear arrangement;
b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; and
c) at least one of said 9 amino acids is a non genetically coded amino acid;
wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.